Relevant bibliographies by topics / Infections à Burkholderia – Thérapeutique

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters

Academic literature on the topic 'Infections à Burkholderia – Thérapeutique'

Author: Grafiati
Published: 24 June 2021
Last updated: 5 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Infections à Burkholderia – Thérapeutique.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Infections à Burkholderia – Thérapeutique"

1

Rao, P. Sugandhi, Reetika Dhawan, and P. G. Shivananda. "Burkholderia Pseudomallei Infections." Tropical Doctor 32, no. 3 (July 2002): 174–75. http://dx.doi.org/10.1177/004947550203200321.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dance, D. A. B. "Burkholderia pseudomallei Infections." Clinical Infectious Diseases 30, no. 1 (January 1, 2000): 235–36. http://dx.doi.org/10.1086/313577.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bertholom, Chantal. "Infections associées aux Burkholderia." Option/Bio 28, no. 571-572 (November 2017): 18–20. http://dx.doi.org/10.1016/s0992-5945(17)30266-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Batard, Eric, and Gilles Potel. "Thérapeutique des infections à staphylocoques." EMC - Maladies infectieuses 3, no. 4 (January 2006): 1–8. http://dx.doi.org/10.1016/s1166-8598(06)41682-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pandey, Vivek, SripathiP Rao, Sugandhi Rao, KiranK V. Acharya, and SarabjeetSingh Chhabra. "Burkholderia pseudomalleimusculoskeletal infections (melioidosis) in India." Indian Journal of Orthopaedics 44, no. 2 (2010): 216. http://dx.doi.org/10.4103/0019-5413.61829.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Burns, Jane L., and Lisa Saiman. "BURKHOLDERIA CEPACIA INFECTIONS IN CYSTIC FIBROSIS." Pediatric Infectious Disease Journal 18, no. 2 (February 1999): 155–56. http://dx.doi.org/10.1097/00006454-199902000-00015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Otağ, F., G. Ersöz, M. Şalcıoğlu, Ç. Bal, I. Schneider, and A. Bauernfeind. "Nosocomial bloodstream infections with Burkholderia stabilis." Journal of Hospital Infection 59, no. 1 (January 2005): 46–52. http://dx.doi.org/10.1016/j.jhin.2004.06.034.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bedir Demirdag, Tugba, Aslinur Ozkaya Parlakay, Ismail Selcuk Aygar, Belgin Gulhan, and Saliha Kanik Yuksek. "Major Aspects of Burkholderia gladioli and Burkholderia cepacia Infections in Children." Pediatric Infectious Disease Journal 39, no. 5 (May 2020): 374–78. http://dx.doi.org/10.1097/inf.0000000000002587.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Wang, Guanbo, Paulina Zarodkiewicz, and Miguel A. Valvano. "Current Advances in Burkholderia Vaccines Development." Cells 9, no. 12 (December 11, 2020): 2671. http://dx.doi.org/10.3390/cells9122671.

Full text
Abstract:
The genus Burkholderia includes a wide range of Gram-negative bacterial species some of which are pathogenic to humans and other vertebrates. The most pathogenic species are Burkholderia mallei, Burkholderia pseudomallei, and the members of the Burkholderia cepacia complex (Bcc). B. mallei and B. pseudomallei, the cause of glanders and melioidosis, respectively, are considered potential bioweapons. The Bcc comprises a subset of Burkholderia species associated with respiratory infections in people with chronic granulomatous disease and cystic fibrosis. Antimicrobial treatment of Burkholderia infections is difficult due to the intrinsic multidrug antibiotic resistance of these bacteria; prophylactic vaccines provide an attractive alternative to counteract these infections. Although commercial vaccines against Burkholderia infections are still unavailable, substantial progress has been made over recent years in the development of vaccines against B. pseudomallei and B. mallei. This review critically discusses the current advances in vaccine development against B. mallei, B. pseudomallei, and the Bcc.
APA, Harvard, Vancouver, ISO, and other styles
10

Grund, Megan E., Jeon Soo, Christopher K. Cote, Rita Berisio, and Slawomir Lukomski. "Thinking Outside the Bug: Targeting Outer Membrane Proteins for Burkholderia Vaccines." Cells 10, no. 3 (February 25, 2021): 495. http://dx.doi.org/10.3390/cells10030495.

Full text
Abstract:
Increasing antimicrobial resistance due to misuse and overuse of antimicrobials, as well as a lack of new and innovative antibiotics in development has become an alarming global threat. Preventative therapeutics, like vaccines, are combative measures that aim to stop infections at the source, thereby decreasing the overall use of antibiotics. Infections due to Gram-negative pathogens pose a significant treatment challenge because of substantial multidrug resistance that is acquired and spread throughout the bacterial population. Burkholderia spp. are Gram-negative intrinsically resistant bacteria that are responsible for environmental and nosocomial infections. The Burkholderia cepacia complex are respiratory pathogens that primarily infect immunocompromised and cystic fibrosis patients, and are acquired through contaminated products and equipment, or via patient-to-patient transmission. The Burkholderia pseudomallei complex causes percutaneous wound, cardiovascular, and respiratory infections. Transmission occurs through direct exposure to contaminated water, water-vapors, or soil, leading to the human disease melioidosis, or the equine disease glanders. Currently there is no licensed vaccine against any Burkholderia pathogen. This review will discuss Burkholderia vaccine candidates derived from outer membrane proteins, OmpA, OmpW, Omp85, and Bucl8, encompassing their structures, conservation, and vaccine formulation.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Infections à Burkholderia – Thérapeutique"

1

Loupias, Pauline. "Synthèse et étude d'analogues de sidérophores à large spectre antibactérien." Thesis, Amiens, 2020. http://www.theses.fr/2020AMIE0032.

Full text
Abstract:
Ce travail de thèse a consisté à exploiter une nouvelle stratégie thérapeutique pour lutter contre Pseudomonas aeruginosa et Burkholderia pseudomallei, deux bactéries à Gram-négatif particulièrement préoccupantes. Alors que P. aeruginosa qui fait partie des bactéries ESKAPE est responsable de la majorité des infections nosocomiales, B. pseudomallei, anciennement classifiée dans le groupe de Pseudomonas, est impliquée dans la maladie de Whitmore et est considérée par les CDC comme une arme bioterroriste potentielle. Ces deux pathogènes possèdent des résistances naturelles et acquises à de nombreux antibiotiques par efflux ou via un défaut de perméabilité membranaire, ce qui rend les traitements difficiles. Devant cette urgence sanitaire, l'exploitation de la stratégie "Cheval de Troie", pour vectoriser les antibiotiques, peut permettre de restaurer leurs activités. Le fer constitue un micronutriment nécessaire à la survie des bactéries mais il est peu biodisponible du fait de sa faible solubilité dans l'eau. Pour l'acquérir, de nombreuses bactéries synthétisent des molécules de faible poids moléculaire, appelés sidérophores, capables de chélater le fer environnant. Les complexes formés sont alors reconnus spécifiquement par des récepteurs dépendants de TonB afin de transporter le fer au sein des bactéries. Selon leur type, les bactéries expriment différents récepteurs reconnaissant leurs sidérophores endogènes mais aussi des xénosidérophores ou des sidérophores synthétiques. L'utilisation de ces différents types sidérophores pour véhiculer un antibiotique ou un métal toxique tel que le gallium dans la bactérie a déjà conduit à des résultats prometteurs. Les objectifs de cette thèse étaient de synthétiser de nouveaux sidérophores de structure pipérazinique, de nouveaux conjugués sidérophore-antibiotiques et des complexes toxiques sidérophore-gallium. Des études physico-chimique et biologique ont aussi été menée afin de valider l'intérêt des structures choisies dans la chimiothérapie anti-infectieuse
This work consisted in exploiting a new therapeutic strategy to fight Pseudomonas aeruginosa and Burkholderia pseudomallei, two Gram-negative bacteria particularly concerning. While P. aeruginosa, which is part of the ESKAPE bacteria, is responsible for the majority of nosocomial infections, B. pseudomallei, formerly classified in the Pseudomonas group, is involved in Whitmore's disease and is considered by the CDC as a potential bioterrorist weapon. These two pathogens have natural and acquired resistance to many antibiotics by efflux or via a lack of membrane permeability, which makes treatment difficult. Facing this health emergency, the use of the "Trojan Horse" strategy to vectorize antibiotics can help restore their activities. Iron is a micronutrient necessary for the survival of bacteria, but it is not very bioavailable due to its low solubility in water. To acquire it, many bacteria synthesize molecules of low molecular weight, called siderophores, capable of chelating the surrounding iron. The complexes formed are then recognized specifically by TonB-dependent receptors in order to transport iron within bacteria. Depending on their type, bacteria express different receptors recognizing their endogenous siderophores but also xenosiderophores or synthetic siderophores. The use of these different kinds of siderophores to carry an antibiotic or a toxic metal such as gallium into the bacteria has already led to promising results. The objectives of this PhD were to synthesize new siderophores of piperazine structure, new siderophore-antibiotic conjugates and toxic siderophore-gallium complexes. Physico-chemical and biological studies were also carried out in order to validate the interest of the structures chosen in anti-infectious chemotherapy
APA, Harvard, Vancouver, ISO, and other styles
2

Biot, Fabrice. "Etude des mécanismes de résistance par efflux chez les burkholderia pathogènes." Thesis, Aix-Marseille, 2012. http://www.theses.fr/2012AIXM5038.

Full text
Abstract:
Burkholderia pseudomallei et Burkholderia mallei sont respectivement les agents biologiques responsables de la mélioïdose et de la morve. Pour déterminer si les échecs thérapeutiques étaient dus à l'émergence d'une résistance acquise durant le traitement antibiotique, nous avons sélectionné des souches de Burkholderia thailandensis, modèle d'étude, B. pseudomallei et B. mallei, avec différents antibiotiques : le chloramphénicol, la doxycycline et le triméthoprime-sulfaméthoxazole. Les Burkholderia ont montré qu'elles étaient capables de développer une multirésistance in vitro en réponse à chaque antibiotique utilisé dans le traitement oral de la mélioïdose ou de la morve. Pour comprendre les mécanismes de résistance impliqués, nous avons étudié les aspects moléculaires et génétiques de la résistance chez B. thailandensis par des méthodes protéomiques et transcriptomiques. Nous avons développé une méthode pour quantifier l'expression des gènes de pompes d'efflux par RT-PCR quantitative après normalisation sur plusieurs gènes de référence. Ces méthodes nous ont permis d'identifier la surproduction séquentielle de trois pompes d'efflux de type RND : BpeAB-OprB, AmrAB-OprA et BpeEF-OprC, toutes induites par le chloramphénicol ou la doxycycline chez les souches multirésistantes. L'étude de mutants déficients en pompe d'efflux nous a permis de mieux appréhender les relations étroites entre ces trois pompes et a confirmé que l'efflux actif était le principal mécanisme impliqué cette résistance induite
Burkholderia pseudomallei and Burkholderia mallei are respectively the causative agents of melioidosis and glanders. To determine whether treatment failures were due to the emergence of acquired resistance during antibiotic treatment, we selected strains of B. pseudomallei, B. mallei, and Burkholderia thailandensis, used as a study model of these two pathogenic bacteria, with structurally unrelated antibiotics: chloramphenicol, doxycycline and trimethoprim-sulfamethoxazole. We showed that Burkholderia were able to develop multidrug resistance in vitro in response to each of theses antibiotics used in the oral treatment of melioidosis and glanders. To understand the resistance mechanisms involved, we studied the molecular and genetic aspects of resistance in B. thailandensis by proteomic and transcriptomic methods. We have developed a method to quantify efflux pumps gene expression by quantitative RT-PCR after normalization with several reference genes. These methods allowed us to identify sequential overproduction of three RND efflux pumps: BpeAB-OprB, AmrAB-OprA and BpeEF-OprC, all induced by chloramphenicol or doxycycline in multiresistant strains. The study of mutants respectively defective in one of these efflux pumps has allowed us to better understand the close relationship between these three pumps and confirmed that active efflux acted as a major mechanism involved in the induced resistance
APA, Harvard, Vancouver, ISO, and other styles
3

Nahum, Joseph. "Thérapeutique des infections à Herpes simplex virus." Paris 5, 1999. http://www.theses.fr/1999PA05P200.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nivoix, Yasmine. "Infections fongiques invasives : épidémiologie et optimisation thérapeutique." Strasbourg, 2009. http://www.theses.fr/2009STRA2006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pilatova, Martina. "Infections of Drosophila melanogaster with pathogens : Mycobacterium marinum and Burkholderia thailandensis." Thesis, King's College London (University of London), 2012. https://kclpure.kcl.ac.uk/portal/en/theses/infections-of-drosophila-melanogaster-with-pathogens(e7aa5890-68d4-470d-8c16-58dbc6a7036a).html.

Full text
Abstract:
The first part of this thesis focuses on infection of Drosophila with Mycobacterium marinum. Tuberculosis remains one of the most widespread infectious diseases in the world affecting approximately one third of the world’s population1. The bacterium that causes this serious affliction is Mycobacterium tuberculosis, a Biosafety Level 3 agent. This bacterium’s close relative, M. marinum, causes a tuberculosis-like disease in fish and frogs, but does not require special working conditions. In the fruit fly, Drosophila melanogaster, M. marinum prevents phagosomal acidification, permitting it to survive in fly macrophages. Drosophila is thus a genetically tractable model for the study of some stages of tuberculosis. To understand the pathology of M. marinum infection in the fly, I have analysed the potential role of several genes mainly by survival assays, quantification of antimicrobial peptide expression, and microscopy. A phenotype emerged in a macrophage-specific knockdown of the Drosophila phagocytic receptor Nimrod C3. The second part of this thesis focuses on infections of Drosophila with Burkholderia thailandensis. B. thailandensis is a Gram-negative bacterium closely related to Burkholderia pseudomallei, the causative agent of melioidosis. The study revealed that B. thailandensis was pathogenic in the fly; it activated the fly immune system and antimicrobial peptides were expressed. Despite the strong immune response, this infection is lethal and kills Drosophila within two days. This result suggests that the bacterium is resistant to antimicrobial peptides; similar findings have been reported in the case of the B. pseudomallei resistance to a human antimicrobial peptide in vitro. Overall, this work focuses on host factors involved in immunity to infection and the generation of pathology in intracellular bacterial infections. In each case, we have used pathogens closely related to serious human pathogens, with the aim of identifying conserved mechanisms of pathogenesis and immunity. Along the way, I have generated several experimental tools that will be useful both for the study of these specific infections and for the analysis of infection biology more generally.
APA, Harvard, Vancouver, ISO, and other styles
6

Delaunay, Isabelle. "La mucoviscidose : complications infectieuses pulmonaires : stratégies thérapeutiques médicale et chirurgicale, à propos de 4 observations d'adultes jeunes." Caen, 1990. http://www.theses.fr/1990CAEN3097.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Jeannot, Anne-Cécile. "Diagnostic des infections grippales par PCR temps réel." Bordeaux 2, 2005. http://www.theses.fr/2005BOR2P040.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zupanc, Kauss Tina. "Intérêt thérapeutique et formulation galénique des polyphénols dans le traitement des infections et inflammations." Bordeaux 2, 2007. http://www.theses.fr/2007BOR21501.

Full text
Abstract:
La réponse immune pro-inflammatoire peut parfois entraîner des processus pathologiques, comme la destruction de la matrice articulaire dans le cas de la polyarthrite rhumatoide ou une cachexie mortelle dans le cas de la trypanosomose africaine. Dans ces deux pathologies, des nouveaux traitements sont nécessaires pour une meilleure prise en charge des malades. Les flavonols, des molécules naturelles végétales peu toxiques, pourraient apporter cette alternative thérapeutique, mais leurs effets anti-inflammatoires et anti-parasitaires doivent être démontrés et/ou caractérisés. Notre travail consistait à évaluer le potentiel thérapeutique de deux flavonols : la quercétine et la rutine. Nous avons étudié leurs effets à des doses non toxiques pour les cellules humaines sur les médiateurs d'inflammation macrophagiques au niveau génomique et protéique. L'inhibition duTNFα, de l'IL1β et du NO a pu être mise en évidence in vitro. L'effet anti-inflammatoire a été confirmé in vivo sur un modèle d'arthrite chez le rat (un modèle proche de la polyarthrite rhumatoide humaine) où l'amélioration des scores cliniques et de la cachexie était corrélée à la diminution des marqueurs inflammatoires sériques. Par ailleurs, l'effet trypanocide de la rutine et de la quercétine a été démontré et étudié in vitro pour déterminer sa cinétque et les relations dose-réponse. De plus, l'effet trypanocide de la vitamine C a pu être démontré in vitro. Les études in vivo devront vonfirmer l'efficacité de ces molécules dans le cas de la trypanosomose africaine. Une première approche de développement galénique a été réalisée pour améliorer la biodisponibilité et donc les effets thérapeutiques des flavonols
Immune response can become a pathological process, leading to a joint matrix destruction in rheumatoid arthritis or to a chronic cachexia in African trypanosomosis. In both pathologies, new therapeutics are needed for a better patients care. Flavonols, non toxic vegetal compounds, could bring a therapeutic alternative in these diseases, but their anti-inflammatory and anti-parasitic effects should be proved and/or characterized. We evaluated therefore the therapeutic potential of two flavonols, quercetin and rutin, in view of their use in human medicine. The effects of non toxic doses of flavonols on macrophage inflammatory mediators' gene transcription and protein expression were studied. In vitro inhibition of TNFα? il1β and NO was also confirmed on rat adjuvant-induced arthritis model, showing a correlation between clinical signs of inflammation (clinical scores and cachexia) and serum inflammatory mediators. In addition, quercetin and rutin trypanocidal effects were demonstrated and the kinetics and dose-response relationship studied. Furthermore, the in vitro trypanocydal effect of vitamin C was highlighted. In vivo studies should confirm the effectiveness of these molecules in African trupanosomosis. A first galenic approach was also conducted in order to improve the bioavailability and consequent therapeutic effects of flavonols
APA, Harvard, Vancouver, ISO, and other styles
9

Berthelot, Philippe. "Exploration endoscopique et instrumentation thérapeutique comme sources d'infection respiratoire nosocomiale." Saint-Etienne, 1993. http://www.theses.fr/1993STET6411.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Maulner, Stéphanie. "Les endolysines de Clostridium difficile : Potentiel thérapeutique pour traiter les infections à C. difficile (ICD)." Mémoire, Université de Sherbrooke, 2010. http://savoirs.usherbrooke.ca/handle/11143/4059.

Full text
Abstract:
Clostridium difficile, un bacille à Gram positif anaérobie strict qui forme des spores, est un pathogène opportuniste responsable de simples diarrhées ou de colites pseudomembraneuses qui peuvent provoquer la mort. Le traitement de base réside en l'arrêt des antibiotiques qui ont détruit la flore de l'hôte et provoqué les symptômes, ou en la prescription de vancomycine et/ou de métronidazole. Malheureusement, l'efficacité de ces antibiotiques est variable et le nombre de rechutes est élevé. En outre, de plus en plus de souches deviennent résistantes aux antibiotiques. C'est pour cette raison qu'un besoin d'alternatives thérapeutiques s'est fait ressentir. Une des approches prometteuses est l'utilisation des endolysines, qui sont des enzymes hydrolytiques encodées par les bactériophages et qui se sont déjà révélées être efficaces contre plusieurs bactéries à Gram positif. Dans cette étude, nous avons démontré l'activité lytique d'endolysines encodées par des phages de Clostridium difficile sur des cellules vivantes. Différentes endolysines ont été clonées dans E. coli, exprimées et purifiées, puis leur activité a été vérifiée de plusieurs manières. Certains facteurs biochimiques propres à ces enzymes ont été étudiés, tels que les cofacteurs nécessaires pour une meilleure activité lytique, le pH optimal et le spectre d'efficacité sur différentes souches bactériennes. Finalement, l'étude de ces enzymes comme outil de diagnostic ou de biologie moléculaire est abordée. Les résultats de nos travaux indiquent que les endolysines PlyCD52 et PlyCD38-2 de C. difficile possèdent une faible activité lytique. L'activité des endolysines n'est pas influencée par les cofacteurs Tween 0,5%, Triton 0,1%, MgCl[indice inférieur 2] contrairement à l'EDTA qui inhibe celle-ci. Le pH optimum semble être compris entre 7 et 8,5 et ces enzymes agissent sur différentes souches de C. difficile à l'exception de la souche CD630. Malgré ces résultats encourageants, des travaux supplémentaires seront nécessaires afin de stabiliser les enzymes qui ont une forte tendance à précipiter et d'obtenir une meilleure activité.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Infections à Burkholderia – Thérapeutique"

1

Dariosecq, Jean-Michel. Infection VIH: Mémento thérapeutique 2003. 6th ed. Rueil-Malmaison: Doin, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Powderly, William G. Manual of HIV therapeutics. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Moss, Adrian. HIV and AIDS: Management by the primary care team. Oxford: Oxford University Press, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Auguste, Sturk, International Endotoxin Society, European Shock Society, and European Conference on Intensive Care Medicine (5th : 1990 : Amsterdam, Netherlands), eds. Bacterial endotoxins: Cytokine mediators and new therapies for sepsis : proceedings of the Third International Conference on Endotoxins, held in Amsterdam, the Netherlands, June 7-8, 1990. New York: Wiley-Liss, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Catalán, José. Psychological medicine of HIV infection. Oxford: Oxford University Press, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Adrian, Burgess, Klimes Ivana, and Gazzard Brian, eds. Psychological medicine of HIV infection. Oxford: Oxford University Press, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ramachandran, Raja, and Vivekanand Jha. Renal involvement in other infections. Edited by Vivekanand Jha. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0198_update_001.

Full text
Abstract:
Renal involvement has been described in patients with many other infections and this chapter discusses several of these.Water-borne infections are a common cause of acute kidney injury (AKI) worldwide but especially in tropical regions. Cholera is notoriously dangerous but any other cause of fluid-depletion may achieve the same. Typhoid fever is more likely to cause AKI from its complications than directly, but a small proportion of patients have glomerulonephritis.Meliodosis is caused by the intracellular organism Burkholderia pseudomallei. It typically affects workers in paddy (rice) fields in the rainy season, and may cause a local, genitourinary infection or an acute melioidosis septicaemia with a high incidence of AKI and mortality. Those with other chronic conditions are at greatest risk.Obstetric infections as a result of unsafe deliberate abortion or post-partum are a very common (often the most common) cause of AKI in developing countries, and a major cause of avoidable death in young women.
APA, Harvard, Vancouver, ISO, and other styles
8

Govan, John, and Andrew Jones. Microbiology of CF lung disease. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780198702948.003.0003.

Full text
Abstract:
This chapter presents the microbiology of CF and describes the classical bacterial pathogens including Staphylococcus aureus, Haemophilus influenza, Pseudomonas aeruginosa and organisms of the Burkholderia cepacia complex. The dominant of these is P. aeruginosa. Infections with other opportunistic pathogens including non-tuberculous mycobacteria, Stenotrophomonas maltophila, and Achromobacter (Alcaligenes) xylosoxidans are also encountered. This chapter details measures to prevent the onset of chronic infection with these organisms include regular screening of respiratory tract samples for bacterial pathogens and the use of aggressive antibiotic therapy to eradicate initial infection before the pathogen can adapt to the environment of the CF lung. Patient-to-patient spread of transmissible strains of bacterial pathogens has led to the implementation of strict infection control measures at CF centres, including patient segregation. In addition to bacterial pathogens, the contribution of fungal infection in CF lung disease is increasingly recognized.
APA, Harvard, Vancouver, ISO, and other styles
9

Des bactéries et des hommes. Privat, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Infections à Burkholderia – Thérapeutique"

1

Peters, Danielle L., Fatima Kamal, and Jonathan J. Dennis. "Burkholderia." In Laboratory Models for Foodborne Infections, 271–87. Boca Raton : CRC Press/Taylor & Francis, 2017. | Series: Food microbiology series: CRC Press, 2017. http://dx.doi.org/10.1201/9781315120089-18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Drevinek, Pavel, and Eshwar Mahenthiralingam. "Burkholderia." In Molecular Typing in Bacterial Infections, 301–8. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-62703-185-1_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Klastersky, J., and M. Aoun. "Prévention et traitement des infections." In Thérapeutique du cancer, 151–65. Paris: Springer Paris, 2011. http://dx.doi.org/10.1007/978-2-8178-0021-9_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Snell, Gregory, Olivia Smibert, and Elizabeth Tullis. "Burkholderia in Transplant: Important to Speciate and Important to Treat." In Emerging Transplant Infections, 1–19. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-01751-4_22-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Snell, Gregory, Olivia Smibert, and Elizabeth Tullis. "Burkholderia in Transplant: Important to Speciate and Important to Treat." In Emerging Transplant Infections, 391–408. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-25869-6_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kaiser, Jean-Daniel, Joël Leroy, and Samuel Limat. "Traitement des infections osseuses." In Pharmacie Clinique et Thérapeutique, 825–32. Elsevier, 2018. http://dx.doi.org/10.1016/b978-2-294-75077-9.00046-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kaiser, Jean-Daniel, Joël Leroy, and Samuel Limat. "Traitement des infections digestives." In Pharmacie Clinique et Thérapeutique, 843–52. Elsevier, 2018. http://dx.doi.org/10.1016/b978-2-294-75077-9.00048-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Navas, Dominique, Jean-François Huon, and Stéphane Ploteau. "Traitement des infections gynécologiques." In Pharmacie Clinique et Thérapeutique, 815–24. Elsevier, 2018. http://dx.doi.org/10.1016/b978-2-294-75077-9.00045-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Singlas, Éric, and Nicole Desplaces. "Traitement des infections osseuses." In Pharmacie clinique et thérapeutique, 1005–14. Elsevier, 2008. http://dx.doi.org/10.1016/b978-2-294-06234-6.50050-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Steinmetz, Jean-Philippe, Marie-Odile Decroix†, Jean-Philippe Steinmetz, and Matthieu Roustit. "Traitement des infections digestives." In Pharmacie clinique et thérapeutique, 1029–40. Elsevier, 2008. http://dx.doi.org/10.1016/b978-2-294-06234-6.50052-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Infections à Burkholderia – Thérapeutique' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography